ELOCTATE IV 2000, from Sanofi, contains Efflaloctocog alpha (genetically recombination), a long-acting Factor VIII replacement therapy used for prophylaxis and treatment of bleeding in hemophilia A. It is supplied as 2,000 IU 1 bottle with dissolving liquid (YJ code: 6343442D6024).
ELOCTATE IV 2000
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →